Cytokeratin 19 antibody | A53-B/A2
siRNA Validated
Mouse antiHuman cytokeratin 19 antibody, clone A53-B/A2 (5552-9009) used for the identification of CK19 expressing cells and tissues by immunofluorescence.
Image caption:
Assessment of alternative markers to delineate hMEC subpopulations using high-content screening. a Immunofluorescence staining of hMECs with DAPI (white) and antibodies against K14 (red), K19 (blue) and K8/18 (green; top panel) or K5 (green; bottom panel). Images acquired at 20× magnification using INCA. b Proportional Venn diagrams depict the mean overall proportions and overlap of K14, K8/18 and K19 expression (top) and K14, K5 and K19 expression (bottom) in first-passage hMEC cultures for donor Q626. c IHC staining of K5 and K8/18 on FFPE sections of normal human breast. Staining for K5 (top left, 10×) delineates both basal cells (i; top right, 20×) and luminal cells (ii; bottom left, 20×). Staining for K8/18 (bottom right, 10×) preferentially delineates basal cells. DAPI 4',6-diamidino-2-phenylindole, K5 cytokeratin 5, K8/18 cytokeratin 8/18, K14 cytokeratin 14, K19 cytokeratin 19
From: Johnston RL, Wockner L, McCart Reed AE, Wiegmans A, Chenevix-Trench G, Khanna KK, Lakhani SR, Smart CE.
High content screening application for cell-type specific behaviour in heterogeneous primary breast epithelial subpopulations.
Breast Cancer Res. 2016 Feb 9;18(1):18.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse antiHuman cytokeratin 19 antibody, clone A53-B/A2 (5552-9009) used for the identification of CK19 expressing cells and tissues by immunohistochemistry and immunofluorescence.
Image caption:
High-content screening of normal human mammary epithelial cells (hMECs). a Schematic representation of a normal human mammary duct in vivo showing the major cell types: basal cells (red) and luminal cells (blue). b Light micrographs of immunohistochemical staining of K19 and K14 on FFPE sections of normal human breast delineating luminal and basal cells respectively. c Representative image of immunofluorescence staining of primary hMECs acquired using the IN Cell Analyser 2000 (GE Healthcare, Silverwater, NSW, Australia) at 20× magnification. Cells were stained for K14 (red) and K19 (blue) and counterstained with DAPI (white). Areas of the four possible cell phenotypes are indicated (arrows): double negative or K14-/K19-; double positive or K14+/K19+; K14+ (K14+/K19-); and K19+ (K14-/K19+). d Identification of cell phenotype on a single cell basis using digital image analysis. The image analysis protocol defines cells based on nuclear segmentation (first column), then subsequently measures the average intensity of K14 (second column) and K19 (third column) within each cell. The four possible outcomes for K14 and K19 are shown by row. e Intensity distributions for K14 (left panels) and K19 (right panels) in primary hMEC culture of negative secondary only control (black) and stained samples plotting their respective cytokeratin distribution (K14, red; K19, blue). f Subpopulation frequency of the four cell phenotypes in the first passage of hMECs for five donors. Mean subpopulation frequencies across (n = 5–6) technical replicates were calculated as the average percentage of total cell number within each well for each of the five individual donors (± standard error of the mean (SEM)). g Subpopulation frequency with passage and enrichment using FACS (Fluorescence-activated cell sorting). Cells from reduction mammoplasties were dissociated and cultured in vitro (P1). After 5–7 days, cells were harvested and sorted based on expression of CD10 and MUC1 using FACS. CD10+, MUC1+ and unsorted (US) cells were cultured for 5 days (P2) before fixation and analysis of population heterogeneity. Mean subpopulation frequencies were calculated as the average percentage of total cell number within each well for each sample (± SEM). DAPI 4',6-diamidino-2-phenylindole, FACS fluorescence-activated cell sorting, K14 cytokeratin 14, K19 cytokeratin 19, P1 passage 1, P2 passage 2
From: Johnston RL, Wockner L, McCart Reed AE, Wiegmans A, Chenevix-Trench G, Khanna KK, Lakhani SR, Smart CE.
High content screening application for cell-type specific behaviour in heterogeneous primary breast epithelial subpopulations.
Breast Cancer Res. 2016 Feb 9;18(1):18.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse antiHuman cytokeratin 19 antibody, clone A53-B/A2 (5552-9009) used for the identification of CK19 expressing cells and tissues by immunofluorescence.
Image caption:
Assessment of alternative markers to delineate hMEC subpopulations using high-content screening. a Immunofluorescence staining of hMECs with DAPI (white) and antibodies against K14 (red), K19 (blue) and K8/18 (green; top panel) or K5 (green; bottom panel). Images acquired at 20× magnification using INCA. b Proportional Venn diagrams depict the mean overall proportions and overlap of K14, K8/18 and K19 expression (top) and K14, K5 and K19 expression (bottom) in first-passage hMEC cultures for donor Q626. c IHC staining of K5 and K8/18 on FFPE sections of normal human breast. Staining for K5 (top left, 10×) delineates both basal cells (i; top right, 20×) and luminal cells (ii; bottom left, 20×). Staining for K8/18 (bottom right, 10×) preferentially delineates basal cells. DAPI 4',6-diamidino-2-phenylindole, K5 cytokeratin 5, K8/18 cytokeratin 8/18, K14 cytokeratin 14, K19 cytokeratin 19
From: Johnston RL, Wockner L, McCart Reed AE, Wiegmans A, Chenevix-Trench G, Khanna KK, Lakhani SR, Smart CE.
High content screening application for cell-type specific behaviour in heterogeneous primary breast epithelial subpopulations.
Breast Cancer Res. 2016 Feb 9;18(1):18.
This image is from an open access article distributed under the terms of a Creative Commons Attribution License.
Mouse anti Human cytokeratin 19 antibody, clone A53-B/A2 (5552-9009) used to evaluate CK19 expression in human cancer cell lines by western blotting.
Image caption:
CK19 expression was shown by western blot analyses in breast cancer cell lines. 20 μg of each cell line protein was applied in the 12% Acrylamide gel. After transferring to the nitrocellulose membrane, the membrane was incubated using mouse monoclonal CK19 antibody and HRP (horseradish peroxidase) anti-mouse antibody. Then, the protein bands were revealed by the ECL method. The cervical cancer cell line (HeLa) was considered as a negative control.
From: Orafa Z, Karimi N, Keyvani S, Oloomi M.
Quantitative CK19 biomarker detection in breast cancer cell lines.
J Med Life. 2022 Feb;15(2):188-195.
doi: 10.25122/jml-2021-1101.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Mouse anti Human Cytokeratin 19
- Product Type
- Monoclonal Antibody
- Clone
- A53-B/A2
- Isotype
- IgG2a
- Format
- Purified
- Specificity
- Cytokeratin 19
Antibody Quality and Performance Guarantee
| Mouse anti Human cytokeratin 19 antibody, clone A53-B/A2 recognizes the rod domain (aa 312-335) of human cytokeratin 19 (Böttger; et al. 1995) also known as keratin 19 encoded by the KRT19 gene. Cytokeratin 19 is a 400 amino acid intermediate filament protein lacking a C-terminal tail domain, in contrast to all other intermediate filament proteins. Cytokeratin 19 expression is observed in striated muscle where it is involved in forming the association between the contractile apparatus and dystrophin (Stone et al. 2005). Expression is also seen in many ductal and glandular cells together with a restricted set of normal and neoplasic epithelial cells. Mouse anti Human cytokeratin 19 antibody, clone A53-B/A2 detects a band of ~45 kDa in western blotting using an A-549 human alveolar adenocarcinoma cell line lysate. |
|
- Target Species
- Human
- Western Blotting
- In Western blotting 40 kD and 19 kD bands are observed.
- Product Form
- Purified IgG - liquid
- Preparation
- Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
0.09% Sodium Azide (NaN3) - Carrier Free
- Yes
- Immunogen
- Human breast cancer cell line MCF-7.
- Approx. Protein Concentrations
- 1.0 mg/ml
- Regulatory
- For research purposes only
- Guarantee
- 12 months from date of despatch
- Acknowledgements
- PrecisionAb is a trademark of Bio-Rad Laboratories
This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
The PrecisionAb label is reserved for antibodies that meet the defined performance criteria within Bio-Rad's ongoing antibody validation programme. Click here to learn how we validate our PrecisionAb range. Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |  |
||
| Immunofluorescence | |
||
| Immunohistology - Paraffin 1 | |
1/100 | 1/200 |
| Western Blotting | |
- 1This product requires protein digestion pre-treatment of paraffin sections e.g. trypsin or pronase.
The PrecisionAb label is reserved for antibodies that meet the defined performance criteria within Bio-Rad's ongoing antibody validation programme. Click here to learn how we validate our PrecisionAb range. Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using the appropriate negative/positive controls.
- Histology Positive Control Tissue
- Appendix
References for Cytokeratin 19 antibody
-
Karsten, U. et al. (1985) Monoclonal anti-cytokeratin antibody from a hybridoma clone generated by electrofusion.
Eur J Cancer Clin Oncol. 21 (6): 733-40. -
Kasper, M. et al. (1987) Histological evaluation of three new monoclonal anti-cytokeratin antibodies. 1. Normal tissues.
Eur J Cancer Clin Oncol. 23 (2): 137-47. -
Goletz, S. et al. (1997) Novel alphaGalNAc containing glycans on cytokeratins are recognized invitro by galectins with type II carbohydrate recognition domains.
J Cell Sci. 110 ( Pt 14): 1585-96. -
de Neergaard, M. et al. (2010) Epithelial-stromal interaction 1 (EPSTI1) substitutes for peritumoral fibroblasts in the tumor microenvironment.
Am J Pathol. 176: 1229-40. -
Ehlicke, F. et al. (2010) Intervertebral disc regeneration: influence of growth factors on differentiation of human mesenchymal stem cells (hMSC).
Int J Artif Organs. 33 (4): 244-52. -
Johnston, R.L. et al. (2016) High content screening application for cell-type specific behaviour in heterogeneous primary breast epithelial subpopulations.
Breast Cancer Res. 18 (1): 18. -
Orafa, Z. et al. (2022) Quantitative CK19 biomarker detection in breast cancer cell lines.
J Med Life. 15 (2): 188-195.
- RRID
- AB_2133439
- UniProt
- P08727
- Entrez Gene
- KRT19
5552-9009
1212
158824
If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.
View more products with CYTOKERATIN specificity
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
View all Anti-Human ProductsAlways be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up